Dermatology Conference Brief

To view this email as a web page, click here.

Catch up on sessions you may have missed from AAD earlier this month by visiting our conference coverage page.

JAK inhibitors offer hope for vitiligo patients

With several Janus kinase (JAK) inhibitors undergoing clinical trials for vitiligo, their potential approvals will deliver an entirely new treatment strategy, said an expert at AAD.

Immunotherapies for Staphylococcus aureus

Staphylococcus aureus infections are becoming more challenging to treat due to methicillin-resistant Staphylococcus aureus (MRSA), creating a serious public health threat. A better understanding of cutaneous immune mechanisms will identify specific immune mechanisms to target for future vaccines and immunotherapies and help address this serious public health threat.

RUC ensures physician input on procedure codes

As an expert on coding and office management, Mark D. Kaufmann, M.D., explained important role the AMA's Specialty Society Relative Value Update Committee (RUC) plays in code valuation during his presentation at AAD this month.

The immunology and immunotherapy of melanoma

Continued research has led to a variety of melanoma immunotherapy medications, leading to improved survival of melanoma patients. Clinicians should have a firm grasp of the immune mechanisms behind these novel therapies to provide the best advice on treatment and management options of their melanoma patients.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

CONNECT